Non-small cell lung cancers(NSCLCs)oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors  

作　　者：Bopei Cui Lifang Song Qian Wang Kelei Li Qian He Xing Wu Fan Gao Mingchen Liu Chaoqiang An Qiushuang Gao Chaoying Hu Xiaotian Hao Fangyu Dong Jiuyue Zhou Dong Liu Ziyang Song Xujia Yan Jialu Zhang Yu Bai Qunying Mao Xiaoming Yang Zhenglun Liang 

机构地区：[1]Division of Hepatitis and Enterovirus Vaccines,NHC Key Laboratory of Research on Quality and Standardization of Biotech Products,NMPA Key Laboratory for Quality Research and Evaluation of Biological Products,Institute of Biological Products,National Institutes for Food and Drug Control,Bejing,China [2]National Engineering Technology Research Center for Combined Vaccines,Wuhan,China [3]Beijing Minhai Biotechnology Co,Ltd,Beijing,China [4]Taibang Biologic Group,Beijing,China [5]Changchun Institute of Biological Products Co.,Ltd,Changchun,China [6]Shanghai Institute of Biological Products Co,Ltd,Shanghai,China [7]China National Biotec Group Company Limited,Beijing,China

出　　处：《Signal Transduction and Targeted Therapy》2023年第10期5069-5084,共16页信号转导与靶向治疗（英文）

摘　　要：With the continuous in-depth study of the interaction mechanism between viruses and hosts,the virus has become a promising tool in cancer treatment.In fact,many oncolytic viruses with selectivity and effectiveness have been used in cancer therapy.Human enterovirus is one of the most convenient sources to generate oncolytic viruses,however,the high seroprevalence of some enteroviruses limits its application which urges to exploit more oncolytic enteroviruses.

关 键 词：DAMAGE ENTEROVIRUS CANCER 

分 类 号：R734.2[医药卫生—肿瘤]